J&J completes $6.5B acquisition of Momenta

By The Science Advisory Board staff writers

October 1, 2020 -- Johnson & Johnson has successfully completed its acquisition of Momenta Pharmaceuticals in an all-cash transaction for approximately $6.5 billion.

The acquisition was completed on October 1. Shares of Momenta were purchased by Johnson & Johnson's tender offer for $52.50 per share. As a result, Momenta's common stock will be delisted from the Nasdaq Global Select Market.

The acquisition will strengthen Johnson & Johnson's presence in the rare disease medicines space.

National Institutes of Health launches 4th phase III COVID-19 vaccine study
A phase III clinical trial evaluating the investigational Janssen COVID-19 vaccine Ad26.COV2.S for the prevention of symptomatic COVID-19 in a single-dose...
J&J calls for applicants for women in STEM award
Johnson & Johnson is now accepting applications for its 2021 women in STEM disciplines award.
J&J to acquire Momenta for $6.5B
Johnson & Johnson has entered an agreement to acquire Momenta Pharmaceuticals in an all-cash transaction for approximately $6.5 billion with...

Copyright © 2020 scienceboard.net


Conferences
HPLC 2022
June 18-23
San Diego, California United States
Connect
Science Advisory Board on LinkedIn
Science Advisory Board on Facebook
Science Advisory Board on Twitter